Comparison of the Year Ended November 30, 2025 to the Year Ended November 30, 2024 November 30, November 30, ... to the year ended November 30, 2024 ... Working Capital Deficiency November 30, November 30,.
During the six months ended November 30, 2025, we generated $-0- (unaudited) in revenue, compared to $3,750 (unaudited) in revenue during the six months ended November 30, 2024, all of which was ...
As of November 30, 2025, the Sponsor received $500,000 from the total $500,000 in loans and has not financed Quartzsea's transaction expenses ... As of November 30, 2025, we had cash of $12,095 and a working capital deficit of $649,389.
Comparison of the Three Months Ended November 30, 2025, with the Three Months Ended November 30, 2024 ... Comparison of the Nine Months Ended November 30, 2025 with the Nine Months Ended November 30, 2024.
For the year ended November 30, 2025, we had a net loss of $731,371 which consists of formation and operating costs of $1,131,512, partially offset by interest earned on cash and investments held of $400,141 .
Our only activities from September 28, 2023 (inception) through November 30, 2025, were organizational activities and those necessary to consummate the IPO, and subsequent to the IPO, identifying a target company for an initial business combination.
FORT WASHINGTON, PA / ACCESSNewswire / March 4, 2026 / CCA Industries, Inc. (OTC.CAWW) today announced its financial results for the fiscal year ended November 30, 2025 ....
Reports Financial Results for the Year Ended November 30, 2025 ... (OTC.CAWW) today announced its financial results for the fiscal year ended November 30, 2025 ... today reported its financial results for the fiscal year ended November 30, 2025.
Comparison of Results of Operations for the Year Ended November 30, 2025, and the Year Ended November 30, 2024 ... November 30, 2025, as compared with using $168,805 for the year ended November 30, 2024.
) Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025 ... cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2025.
Commission revenue totaled $312,389 and $95,584 for the fiscal year ended November 30, 2025 and November 30, 2024 respectively ... Net sales for the fiscal years ended November 30, 2025 and November 30, ...